title: rhG-CSF effect on mixed lymphocyte cultures and circulating soluble HLA antigen levels in volunteer stem cell donors.
abstract: OBJECTIVE
  Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is a cytokine widely used in the procurement of peripheral blood stem cells (PBSC) from donors for allogeneic hematopoietic cell transplantation. Therefore, we were interested in its immediate and long-term effects on cellular and soluble factors known to be involved in the immune response.
  
  
  METHODS
  We studied 35 PBSC donors by mixed lymphocyte culture (MLC) and lymphocyte transformation test (LTT), and 41 for soluble plasma factors (soluble human leukocyte antigen [sHLA]-G, -class I, -DR, and interleukin [IL]-10) pre and 5 days post initial rhG-CSF administration, respectively. In addition, 10 donors were reexamined at an average of 2 months (3-16 weeks) post-rhG-CSF.
  
  
  RESULTS
  At 5 days post-rhG-CSF the donors presented a significant (p < 0.05) decrease of MLC, LTT mitogen, and recall antigen reactions. Plasma levels of sHLA-G, -class I, -DR, and IL-10 (p < 0.005 each) were significantly increased. The changes in IL-10 but not in sHLA were significantly (p < 0.05) correlated with LTT responses. In the 2-month follow-up there was no significant difference in alloreactivity and LTT reactions as compared to the pre-rhG-CSF results. The results generated after 3 to 16 weeks did not depend on the time point of investigation. Consistently, soluble factors decreased to pre-rhG-CSF levels.
  
  
  CONCLUSIONS
  rhG-CSF administration suppresses cellular immune functions within 5 days and increases sHLA and IL-10 plasma levels. These immunomodulatory effects appear to be short-term only and vanished at an average of 2 months after rhG-CSF application.
authors.affiliation: Institute of Immunology, University Hospital, Essen, Germany.
authors.forename: Monika
authors.initials: M
authors.lastname: Lindemann
authors.forename: Vera
authors.initials: V
authors.lastname: Rebmann
authors.forename: Hellmut D
authors.initials: HD
authors.lastname: Ottinger
authors.forename: Keiko
authors.initials: K
authors.lastname: Schmolke
authors.forename: Ernst
authors.initials: E
authors.lastname: Kreuzfelder
authors.forename: Hans
authors.initials: H
authors.lastname: Grosse-Wilde
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000494:pharmacology; D006680:HLA Antigens / Q000097:blood*; D006684:HLA-DR Antigens / Q000097:blood; D059951:HLA-G Antigens; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects*; D015395:Histocompatibility Antigens Class I / Q000097:blood; D006801:Humans; D007107:Immune System / Q000187:drug effects*; D016753:Interleukin-10 / Q000097:blood; D008213:Lymphocyte Activation / Q000187:drug effects; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011994:Recombinant Proteins; D014019:Tissue Donors
chemical_list: D006680:HLA Antigens; D006684:HLA-DR Antigens; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I; D011994:Recombinant Proteins; D016753:Interleukin-10; D016179:Granulocyte Colony-Stimulating Factor